[[Nemonapride]]

CATEGORIES: Pyrrolidines, Benzamides, Phenol ethers, Organochlorides

Nemonapride (Emilace) is an atypical antipsychotic approved in Japan for the treatment of schizophrenia. It was launched by Yamanouchi in 1991. Nemonapride acts as a D2 and D3 receptor antagonist, and is also a potent 5-HT1A receptor agonist. It has affinity for sigma receptors.

==See also==

==References==


